|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
198,664,000 |
Market
Cap: |
N/A |
Last
Volume: |
1,335,128 |
Avg
Vol: |
625,139 |
52
Week Range: |
$14.24 - $14.24 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Diagnostic Substances |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-01-25 |
2023-10-24 |
2023-04-25 |
2022-04-25 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Glaxosmithkline Plc |
Director |
|
2012-08-02 |
4 |
B |
$14.25 |
$892,708,151 |
I/I |
62,646,186 |
233,716,708 |
2.25 |
- |
|
Glaxosmithkline Plc |
Director |
|
2012-08-01 |
4 |
B |
$14.25 |
$81,035,689 |
I/I |
5,686,715 |
171,070,522 |
2.25 |
- |
|
Glaxosmithkline Plc |
Director |
|
2012-08-01 |
4 |
B |
$14.25 |
$25,481,651 |
I/I |
1,788,186 |
165,383,807 |
2.25 |
- |
|
Watkins Thomas |
Chief Executive Officer |
|
2012-07-30 |
4/A |
D |
$14.25 |
$149,185 |
D/D |
(10,469) |
0 |
|
- |
|
Simpson Curran |
Sr. VP, Operations |
|
2012-07-30 |
4/A |
D |
$14.25 |
$375,260 |
D/D |
(26,334) |
0 |
|
- |
|
Glaxosmithkline Plc |
Director |
|
2012-07-30 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
158,660,878 |
|
- |
|
Glaxosmithkline Plc |
Director |
|
2012-07-30 |
4 |
B |
$14.25 |
$70,320,088 |
I/I |
4,934,743 |
163,595,621 |
2.25 |
- |
|
Danzig Richard J |
Director |
|
2012-07-30 |
4 |
D |
$14.25 |
$104,510 |
D/D |
(7,334) |
0 |
|
- |
|
Danzig Richard J |
Director |
|
2012-07-30 |
4 |
D |
$14.25 |
$59,366 |
D/D |
(4,166) |
7,334 |
|
- |
|
Karabelas Argeris N |
Director |
|
2012-07-30 |
4 |
D |
$14.25 |
$253,308 |
D/D |
(17,776) |
0 |
|
- |
|
Karabelas Argeris N |
Director |
|
2012-07-30 |
4 |
D |
$14.25 |
$59,366 |
D/D |
(4,166) |
17,776 |
|
- |
|
Baxter Allan |
Director |
|
2012-07-30 |
4 |
D |
$14.25 |
$35,625 |
D/D |
(2,500) |
0 |
|
- |
|
Goddard Colin |
Director |
|
2012-07-30 |
4 |
D |
$14.25 |
$93,480 |
D/D |
(6,560) |
0 |
|
- |
|
Goddard Colin |
Director |
|
2012-07-30 |
4 |
D |
$14.25 |
$59,366 |
D/D |
(4,166) |
6,560 |
|
- |
|
Young Robert C |
Director |
|
2012-07-30 |
4 |
D |
$14.25 |
$328,006 |
D/D |
(23,018) |
0 |
|
- |
|
Young Robert C |
Director |
|
2012-07-30 |
4 |
D |
$14.25 |
$197,135 |
D/D |
(13,834) |
18,852 |
|
- |
|
Lamattina John L |
Director |
|
2012-07-30 |
4 |
D |
$14.25 |
$610,513 |
D/D |
(42,843) |
0 |
|
- |
|
Lamattina John L |
Director |
|
2012-07-30 |
4 |
D |
$14.25 |
$59,366 |
D/D |
(4,166) |
42,843 |
|
- |
|
Morrow George J |
Director |
|
2012-07-30 |
4 |
D |
$14.25 |
$154,385 |
D/D |
(10,834) |
0 |
|
- |
|
Morrow George J |
Director |
|
2012-07-30 |
4 |
D |
$14.25 |
$59,366 |
D/D |
(4,166) |
10,834 |
|
- |
|
Gowen Maxine |
Director |
|
2012-07-30 |
4 |
D |
$14.25 |
$247,138 |
D/D |
(17,343) |
0 |
|
- |
|
Gowen Maxine |
Director |
|
2012-07-30 |
4 |
D |
$14.25 |
$161,312 |
D/D |
(11,320) |
13,177 |
|
- |
|
Norden Gregory |
Director |
|
2012-07-30 |
4 |
D |
$14.25 |
$59,366 |
D/D |
(4,166) |
0 |
|
- |
|
Norden Gregory |
Director |
|
2012-07-30 |
4 |
D |
$14.25 |
$47,510 |
D/D |
(3,334) |
4,166 |
|
- |
|
Lawlor Augustine |
Director |
|
2012-07-30 |
4 |
D |
$14.25 |
$604,613 |
D/D |
(42,429) |
0 |
|
- |
|
388 Records found
|
|
Page 1 of 16 |
|
|